Ferric Bepectate not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Iron Deficiency Anemia (IDA)
- Main trialPhase 3
- “The goal of this clinical trial is to see if a new intravenous iron formulation (Ferric Bepectate IV Injection) can treat adult patients with iron deficiency anemia (IDA) by increasing blood hemoglobin (Hb) as an established formulation (Ferric carboxymaltose). It will also learn about the safety of Ferric Bepectate IV Injection. The main questions it aims to answer are: * Does hemoglobin increase by the same amount 6 weeks after each treatment? * What medical problems do participants have when being treated with the drug? Researchers will compare single dose treatment plans of Ferric…”In the company’s words, NCT07687784 on ClinicalTrials.gov
- Other names
- Feramyl
Other drugs for Iron Deficiency Anemia (IDA)
- SutacimigHemab ApS · Phase 3
- FerumoxytolAMAG Pharmaceuticals, Inc. · Phase 3
- Ferric derisomaltoseSichuan Huiyu Pharmaceutical Co., Ltd · Phase 1
Coming up1
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Jun 2028 | A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026